Information
Regulated n.
20259-17-2026Diffusion Start Date/Time July 6, 2026 17:45:11Euronext Growth Milan
Company: LABORATORIO FARMACEUTICO ERFO
User - contact: ERFON02 - Travisano Daniele
Type: 2.4
Reception Date/Time: July 6, 2026 17:45:11 Diffusion Start Date/Time: July 6, 2026 17:45:11 Subject: Laboratorio Farmaceutico Erfo S.p.A. -
Weekly disclosure on own share purchases Press release text
See attachment
PRESS RELEASE
Laboratorio Farmaceutico Erfo S.p.A.
Viale Geki Russo 9 98049 Villafranca Tirrena (ME) VAT No. 03247570835 - Share Capital €1,750,000 fully paid-up Tel. 090 914 6125 - E-mail: info@erfo.it - Certified E-mail: erfospa@pec.it www.erfo.it - www.dietnatural.it
WEEKLY DISCLOSURE
REGARDING THE PLAN FOR THE PURCHASE OF OWN SHARES
Villafranca Tirrena (ME), 07/06/2026
Laboratorio Farmaceutico Erfo S.p.A. (“Erfo” or the “Company”), an Innovative SME and benefit company operating in the nutraceutical sector and listed on Euronext Growth Milan (Ticker: ERFO), with reference to the buyback plan of own shares resolved by the Shareholders' Meeting on April 28, 2026 (the “Meeting”), the commencement of which was approved by the Board of Directors on May 21, 2026 (the “Buyback”), hereby informs that it has purchased, during the week from June 22 to June 26, 2026 inclusive, a total of 15,000 ordinary shares, equal to 0.17% of the share capital, at an average price of Euro 1.16633 per share, for a total consideration of Euro 17,495.00.
The purchases were made through Banca Profilo S.p.A. - the intermediary appointed in full independence and autonomy for the implementation of the Buyback program - in compliance with the applicable legal and regulatory provisions and according to the methods, terms, and conditions contained in the authorization for the purchase and disposal of own shares, granted by the Meeting.
Below is the detail of the purchases made on a daily basis and attached, in detail, are the transactions carried out in the aforementioned period.
DATE NUMBER OF SHARES
PURCHASED AVERAGE UNIT
PRICE (Euro) CONSIDERATION
(Euro)
06/29/2026 5,000 1.17500 5,875.00 € 06/30/2026 1,000 1.18000 1,180.00 € 07/01/2026 3,000 1.15667 3,470.00 € 07/02/2026 3,000 1.17333 3,520.00 € 07/03/2026 3,000 1.15000 3,450.00 €
Total 15,000 1.16633 17,495.00
As of today's date, Erfo therefore directly holds a total of 552,000 own ordinary shares, representing 6.13% of the share capital.
*** This press release is available on the Borsa Italiana website and on the Company's website – www.erfo.it – in the Investor Relations/Press Releases section. For the dissemination of regulated information, Erfo uses the eMarket SDIR circuit, managed by Teleborsa S.r.l., with registered office in Piazza di Priscilla 4, 00199 Rome (www.emarketstorage.it/).
***
IDENTIFIER CODES
PRESS RELEASE
Laboratorio Farmaceutico Erfo S.p.A.
Viale Geki Russo 9 98049 Villafranca Tirrena (ME) VAT No. 03247570835 - Share Capital €1,750,000 fully paid-up Tel. 090 914 6125 - E-mail: info@erfo.it - Certified E-mail: erfospa@pec.it www.erfo.it - www.dietnatural.it Ordinary Shares | ISIN IT0005497885 | Ticker: ERFO
THE COMPANY
Laboratorio Farmaceutico Erfo S.p.A. is an Innovative SME integrated across the entire supply chain, specializing in the formulation, production, and marketing of nutraceutical products. The company is currently at the center of an ecosystem of brands developed mainly through franchising, with over 250 points of sale in Europe, focused on 360-degree nutrition and well-being.
The company operates through 4 business lines: 1. Diètnatural: a format conceived and developed by the company dedicated to the sale of nutraceutical products and continuous support in the nutrition therapy journey; 2. Medical Division: a line of nutraceuticals launched in 2021, dedicated to specific therapeutic areas (gastroenterology, neurology, and musculoskeletal) with significant developments planned in the orthopedic area. 3. Bodysano: a format developed in France and Belgium, which integrates the sale of nutraceutical products, continuous support in nutritional journeys, and innovative aesthetic treatments.
4. Fit&Go: a leading franchising network in Italy in the high-tech fitness and fast fitness sector, offering tailor-made training programs related to well-being and health.
The company's strategy is to invest in the development of its various business lines, particularly through: i) new openings of the different franchising formats in Europe; ii) production and marketing of new products and services related to the world of 360-degree wellness; iii) development of the Medical Division line both in terms of products (i.e., R&D) and commercial network; iv) investments in marketing and digitalization to support the entire ecosystem.
FOR FURTHER INFORMATION:
ISSUER
Erfo
Viale Geki Russo Lo. Pontegallo, 98049 Villafranca T. (Me) Tel. +39 090 914 6125 Daniele Travisano : ir@erfo.it EURONEXT GROWTH ADVISOR
illimity Bank
Via Soperga, 9 - 20124 Milan Tel. +39 02 82849699
Mail: erfo@furstenberg.eu
INVESTOR & MEDIA RELATIONS ADVISOR
IR Top Consulting Via Bigli, 19 - 20121 Milan Tel. +39 02 45473883
Domenico Gentile
ufficiostampa@irtop.com
End of Release n.20259-17-2026 Number of Pages: 4